NLS Pharmaceutics to Present at the 35th Annual Roth Conference
NLS Pharmaceutics to Present at the 35th Annual Roth Conference
ZURICH, SWITZERLAND / ACCESSWIRE / March 1, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced Alex Zwyer, CEO, will be presenting at the 35th Annual Roth Conference.
瑞士苏黎世/ACCESSWIRE/2023年3月1日/瑞士临床阶段生物制药公司NLS制药有限公司(纳斯达克代码：NLSP，NLSPW)今天宣布，首席执行官亚历克斯·兹怀尔将出席第35届Roth年会。该公司专注于为罕见和复杂的中枢神经系统疾病患者发现和开发创新疗法。
Event |
35th Annual Roth Conference |
Date |
March 13, 2023 |
Presentation |
10:00 AM Pacific Time (1:00 PM Eastern Time) |
Location |
Dana Point, CA |
事件 |
第35届Roth年会 |
日期 |
2023年3月13日 |
介绍 |
太平洋时间上午10：00(东部时间下午1：00) |
位置 |
加利福尼亚州达纳角 |
This year's event will consist of 1-on-1 / small group meetings, analyst-selected fireside chats, thematic industry panels, and company presentations by executive management from approximately 400 private and public companies in a variety of growth sectors including: Business Services, Consumer / Health & Wellness, Healthcare, Resources: Oil & Gas / Metals & Mining, Technology, Media & AgTech and Sustainability/ESG.
今年的活动将包括一对一/小组会议、分析师选择的炉边聊天、主题行业小组讨论以及来自各种成长型行业的约400家私营和上市公司的高管管理层的公司演示，这些公司包括：商业服务、消费者/健康和健康、医疗保健、资源：石油和天然气/金属和采矿、技术、媒体和农业技术以及可持续/ESG。
To learn more and submit a registration request, visit
要了解更多信息并提交注册申请，请访问
The live audio webcast and replay will be available in the investor relations section of the Company's website at
现场音频网络直播和重播将在公司网站的投资者关系部分播出，网址为：
About ROTH MKM
关于Roth MKM
ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information, please visit .
Roth MKM是一家关系驱动型投资银行，专注于为成长型公司及其投资者提供服务。我们的全方位服务平台提供融资、高影响力的股票研究、宏观经济学、销售和交易、技术洞察、衍生品策略、并购咨询和企业准入。Roth MKM总部设在加利福尼亚州纽波特海滩，是一家私人所有的员工所有的组织，在美国各地设有办事处。
About NLS Pharmaceutics Ltd.
关于NLS制药有限公司
NLS Pharmaceutics Ltd. (Nasdaq:NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS制药有限公司(纳斯达克代码：NLSP)是一家全球开发期生物制药公司，与世界级合作伙伴和国际公认的科学家网络合作，专注于为患有罕见和复杂的中枢神经系统疾病的患者发现和开发创新疗法，这些患者的医疗需求尚未得到满足。NLS总部设在瑞士，成立于2015年，由一支经验丰富的管理团队领导，该团队在开发和商业化候选产品方面有着良好的记录。欲了解更多信息，请访问。
For additional information:
有关更多信息，请访问：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
Marianne Lambertson(投资者和媒体)
NLS制药有限公司。
+1 239.682.8500
邮箱：ml@nls-pharma.com
SOURCE: NLS Pharmaceutics Ltd.
资料来源：NLS制药有限公司。